Shanghai Yuguan Biotech Co., Ltd.（delonix Bioworks)

This early-stage trial is testing a new vaccine called DX-104 to see if it is safe and triggers an immune response against group B meningococcal bacteria, which can cause meningitis. The study involves 30 healthy adults aged 18 to 50 who will receive either the new vaccine or an …